



Financial Tear Sheet

Corporate Profile

Global Blood Therapeutics, Inc. (GBT) is a clinical-stage biopharmaceutical dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT is developing its lead product candidate, GBT440, for the treatment of sickle cell disease and idiopathic pulmonary fibrosis.

Primary IR Contact

Myesha Lacy

Phone: 650-351-4730

E-mail: investor@gbt.com

Stock Performance

GBT (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price **\$37.77**

Change (%) ▼ 0.87 (2.25%)

Volume 748,533

52 Week Low \$31.50

Market Cap \$2,018,261,791

Rolling EPS -3.42

PE Ratio 0

Shares Outstanding 52,232,448

Data as of 11/13/18 4:00 p.m. ET



Recent Headlines & Events

11/06/18

[GBT Reports Recent Business Progress and Provides Third Quarter 2018 Financial Results](#)

11/06/18

[GBT Announces New Employment Inducement Grants](#)

11/01/18

[GBT Announces Upcoming Data Presentations at 60th American Society of Hematology \(ASH\) Annual Meeting & Exposition](#)

Date

Title

12/03/18 3:00 p.m. ET **[Global Blood Therapeutics Inc at the American Society of Hematology \(ASH\) 2018 Annual Meeting](#)**

SEC Filings

Filing Date

Form

11/06/18

[10-Q](#)

11/06/18

[8-K](#)

09/06/18

[4](#)

08/30/18

[8-K](#)

Corporate Governance

[Ted W. Love, M.D.](#) Chief Executive Officer

[Jeffrey Farrow](#) Chief Financial Officer

[Jung E. Choi](#) Chief Business and Strategy Officer

[Tricia Suvari](#) Chief Legal Officer

[Hing Sham, Ph.D.](#) Senior Vice President, Research

[Peter Radovich](#) Vice President, Program Leadership and Business Strategy

Data provided by Nasdaq. Minimum 15 minutes delayed.